{
    "PFE": [
        {
            "symbol": "PFE",
            "time": 1706572800000000000,
            "displayTime": "Tuesday, January 30 2024",
            "title": "Pfizer Says Paxlovid Revenue Adjustment In Q1 Is Possible",
            "text": "Jan 30 (Reuters) - Pfizer Inc <PFE.N>::PFIZER SPOKESPERSON SAYS POSSIBLE THERE COULD BE REVENUE ADJUSTMENT IN Q1 FOR PAXLOVID AS WINDOW FOR U.S. GOVERNMENT RETURNS STILL OPEN.Further company coverage: PFE.N. ((Reuters.Briefs@thomsonreuters.com;))."
        },
        {
            "symbol": "PFE",
            "time": 1706572800000000000,
            "displayTime": "Tuesday, January 30 2024",
            "title": "Pfizer Records $3.5 Bln Revenue Reversal For COVID Pill Paxlovid In Q4",
            "text": "Jan 30 (Reuters) - Pfizer Inc <PFE.N>::PFIZER CEO, IN PREPARED REMARKS, SAYS THAT CO IS FOCUSED ON EXPANDING RETAIL CONTRACTING AND OFFERINGS TO GAIN MARKET SHARE IN THE RSV VACCINE MARKET.PFIZER EXEC SAYS RECORDED $3.5 BILLION REVENUE REVERSAL FOR COVID PILL PAXLOVID IN THE FOURTH QUARTER.PFIZER SAYS Q4 RESULTS INCLUDED A $1.4 BILLION INTANGIBLE ASSET IMPAIRMENT CHARGE ASSOCIATED WITH ULCERATIVE COLITIS DRUG ETRASIMOD.PFIZER SAYS RECORDED A NEARLY $1 BILLION INTANGIBLE ASSET IMPAIRMENT FOR PNEUMOCOCCAL DISEASE PREVENTION VACCINE PREVNAR 13.Further company coverage: PFE.N. ((Reuters.Briefs@thomsonreuters.com;))."
        }
    ]
}